Sanctuary Advisors LLC Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Sanctuary Advisors LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 33,429 shares of the company’s stock, valued at approximately $75,000.

Several other institutional investors and hedge funds also recently bought and sold shares of XERS. Vanguard Group Inc. increased its position in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. Rosalind Advisors Inc. raised its position in Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock valued at $7,020,000 after acquiring an additional 300,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Xeris Biopharma by 33.9% in the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. AQR Capital Management LLC grew its position in Xeris Biopharma by 4.6% in the second quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock worth $2,684,000 after acquiring an additional 52,074 shares in the last quarter. Finally, Invenomic Capital Management LP increased its stake in shares of Xeris Biopharma by 6.3% during the 1st quarter. Invenomic Capital Management LP now owns 604,512 shares of the company’s stock worth $1,336,000 after purchasing an additional 35,893 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 1.0 %

NASDAQ XERS opened at $3.03 on Tuesday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.26. The stock’s 50 day moving average is $2.81 and its two-hundred day moving average is $2.36. The company has a market capitalization of $449.22 million, a price-to-earnings ratio of -6.47 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million during the quarter, compared to analysts’ expectations of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same period in the previous year, the business posted ($0.14) earnings per share. On average, analysts predict that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research note on Thursday, August 15th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.